Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells-Reference-Cited by-同舟云学术

Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells

Published:2003-06 Issue:6 Volume:94 Page:557-563
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Mukai Motoi,Che Xiao-Fang,Furukawa Tatsuhiko,Sumizawa Tomoyuki,Aoki Shunji,Ren Xiao-Qin,Haraguchi Misako,Sugimoto Yoshikazu,Kobayashi Motomasa,Takamatsu Hideo,Akiyama Shin-ichi

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2003.tb01482.x/fullpdf

Reference35 articles.

1. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [editorial; comment]

2. Signal transduction by wild-type and leukemogenic Abl proteins

3. Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis

4. The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells

5. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological effect of cepharanthine on SARS-CoV-2–induced disease in a Syrian hamster model;Journal of Infection and Chemotherapy;2024-08

2. Differential Regulation of Glucosylceramide Synthesis and Efflux by Golgi and Plasma Membrane Bound ABCC10;Nutrients;2023-01-10

3. Cepharanthine Blocks Presentation of Thyroid and Islet Peptides in a Novel Humanized Autoimmune Diabetes and Thyroiditis Mouse Model;Frontiers in Immunology;2021-12-20

4. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors;Drug Resistance Updates;2020-05

5. Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment;Current Medicinal Chemistry;2019-12-02